ScholarIQanswers from OpenAlex & ORCID
Gregory J. Riely
ResearcherPublications, citations & collaboration network
Gregory J. Riely is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Gregory J. Riely have?
ScholarIQindexed works
Gregory J. Riely has 1,334 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Gregory J. Riely have?
ScholarIQcitation count
Gregory J. Riely has 96,841 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Gregory J. Riely?
ScholarIQh-index
Gregory J. Riely has an h-index of 130 in OpenAlex.
What is the i10-index of Gregory J. Riely?
ScholarIQi10-index
Gregory J. Riely has an i10-index of 355 in OpenAlex.
What is the ORCID of Gregory J. Riely?
ScholarIQorcid
The ORCID for Gregory J. Riely is on the source record.
What is the OpenAlex record for Gregory J. Riely?
ScholarIQopenalex
The OpenAlex for Gregory J. Riely is on the source record.
What are the most-cited papers on Gregory J. Riely?
ScholarIQmost cited works
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis, Élisabeth Brambilla, Masayuki Noguchi, Andrew G. Nicholson, Kim R. Geisinger, Yasushi Yatabe, David G. Beer, Charles A. Powell, Gregory J. Riely, Paul E. Van Schil, Kavita Garg, John H. M. Austin, Hisao Asamura, Valerie W. Rusch, Fred R. Hirsch, Giorgio V. Scagliotti, Tetsuya Mitsudomi, Rudolf M. Huber, Yuichi Ishikawa, James R. Jett, Montse Sánchez‐Céspedes, Jean‐Paul Sculier, Takashi Takahashi, Masahiro Tsuboi, Johan Vansteenkiste, Ignacio I. Wistuba, Pan‐Chyr Yang, Denise R. Aberle, Christian Brambilla, Douglas B. Flieder, Wilbur A. Franklin, Adi F. Gazdar, Michael K. Gould, P S Hasleton, Douglas W. Henderson, Bruce Johnson, David Johnson, Keith M. Kerr, Keiko Kuriyama, Jin Soo Lee, Vincent A. Miller, Iver Petersen, Victor L. Roggli, Rafael Rosell, Nagahiro Saijo, Erik Thunnissen, Ming‐Sound Tsao, David Yankelewitz
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari, Matthew D. Hellmann, Ronglai Shen, Yelena Y. Janjigian, David Barron, Ahmet Zehir, Emmet Jordan, Antonio Omuro, Thomas Kaley, Sviatoslav M. Kendall, Robert J. Motzer, A. Ari Hakimi, Martin H. Voss, Paul Russo, Jonathan E. Rosenberg, Gopa Iyer, Bernard H. Bochner, Dean F. Bajorin, Hikmat Al‐Ahmadie, Jamie E. Chaft, Charles M. Rudin, Gregory J. Riely, Shrujal S. Baxi, Alan L. Ho, Richard J. Wong, David G. Pfister, Jedd D. Wolchok, Christopher A. Barker, Philip H. Gutin, Cameron Brennan, Viviane Tabar, Ingo K. Mellinghoff, Lisa M. DeAngelis, Charlotte E. Ariyan, Nancy Y. Lee, William D. Tap, Mrinal M. Gounder, Sandra P. D’Angelo, Leonard B. Saltz, Zsofia K. Stadler, Howard I. Scher, José Baselga, Pedram Razavi, Christopher A. Klebanoff, Rona Yaeger, Neil H. Segal, Geoffrey Y. Ku, Ronald P. DeMatteo, Marc Ladanyi, Naiyer A. Rizvi, Michael F. Berger, Nadeem Riaz, David B. Solit, Timothy A. Chan, Luc G.T. Morris
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir, Ryma Benayed, Ronak Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R. Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M. Devlin, Matthew D. Hellmann, David Barron, Alison M. Schram, Meera Hameed, Snjezana Doğan, Dara S. Ross, Jaclyn F. Hechtman, Deborah F. DeLair, JinJuan Yao, Diana Mandelker, Donavan T. Cheng, Raghu Chandramohan, Abhinita Mohanty, Ryan Ptashkin, Gowtham Jayakumaran, Meera Prasad, Mustafa Syed, Anoop Balakrishnan Rema, Zhen Y. Liu, Khédoudja Nafa, Laetitia Borsu, Justyna Sadowska, Jacklyn Casanova, Ruben Bacares, Iwona Kiecka, Anna Razumova, Julie B Son, Lisa Stewart, Tessara Baldi, Kerry Mullaney, Hikmat Al‐Ahmadie, Efsevia Vakiani, Adam Abeshouse, Alexander Penson, Philip Jonsson, Niedzica Camacho, Matthew T. Chang, Helen Won, Benjamin Groß, Ritika Kundra, Zachary Heins, Hsiao‐Wei Chen, Sarah Phillips, Hongxin Zhang, Jiaojiao Wang, Angelica Ochoa, Jonathan Wills, Michael Eubank, Stacy B. Thomas, Stuart M. Gardos, Dalicia N. Reales, Jesse Galle, Robert Durany, Roy Cambria, Wassim Abida, Andrea Cercek, Darren R. Feldman, Mrinal M. Gounder, A. Ari Hakimi, James J. Harding, Gopa Iyer, Yelena Y. Janjigian, Emmet Jordan, Ciara M. Kelly, Maeve A. Lowery, Luc G.T. Morris, Antonio Omuro, Nitya Raj, Pedram Razavi, Alexander N. Shoushtari, Neerav Shukla, Tara E. Soumerai, Anna M. Varghese, Rona Yaeger, Jonathan Coleman, Bernard H. Bochner, Gregory J. Riely, Leonard B. Saltz, Howard I. Scher, Paul Sabbatini, Mark E. Robson, David S. Klimstra, Barry S. Taylor, José Baselga, Nikolaus Schultz, David M. Hyman, Maria E. Arcila, David B. Solit, Marc Ladanyi, Michael F. Berger
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
William Pao, Vincent A. Miller, Katerina Politi, Gregory J. Riely, Romel Somwar, Maureen F. Zakowski, Mark G. Kris, Harold Varmus
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne